Prescribing quality improvement: reducing high-dose antipsychotic use

Asta R. Prajapati, Esther Johnston, Uju Ugochukwu, Bohdan Solomka

Research output: Contribution to journalArticlepeer-review

7 Downloads (Pure)


Evidence of efficacy for high‐dose antipsychotic therapy (HDAT) and antipsychotic combinations (AC) is lacking, while evidence of harm is compelling. Significantly higher proportions of Norfolk and Suffolk NHS Foundation Trust (NSFT) patients were being prescribed HDAT and AC compared with the national averages. Here, the authors describe a quality improvement program to rationalise and reduce HDAT and AC prescribing in NSFT, to bring it in line with, or below, the national average. The initiative demonstrates that prescribing culture can be improved through a sustained multi‐professional team approach involving education and training, a targeted campaign, a proactive clinical pharmacy team and pharmacists' support.
Original languageEnglish
Pages (from-to)18-21
Number of pages4
JournalProgress in Neurology and Psychiatry
Issue number3
Publication statusPublished - 31 Aug 2017

Cite this